Companies: 10,795·Total market cap: $144.5T

Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd.

ENLVNASDAQHealthcare● Active

$0.71

+$0.00(+0.59%)

Market Cap$17357253

P/E Ratio—

52W High$2.1

52W Low$0.66

Avg Volume593K

Open$0.72

Beta1.47

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Enlivex Therapeutics Ltd.（ENLV）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · ENLV · 截至 Jun 8, 2026

关键指标

EPS (TTM)$27.02Earnings history

PE Ratio (TTM)0.0×PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding45.7MShares outstanding history

Next EarningsAug 24, 2026Est.Earnings history

探索 Enlivex Therapeutics Ltd. 数据

分析师预测$15 · Buy

股息不分红

盈利EPS $27.04+3804.11%

财务快照

FY 2025Revenue$0.00

202320242025

FY 2025Net Income$1.24B▲ +8329.17% YoY

202320242025

FY 2025EPS$27.04▲ +3804.11% YoY

202320242025

TTM:Revenue: $0.00Net Income: $1.24BEPS: $27.02View income statement →

分析师评级与目标价

Buy4 位分析师

Strong Buy

0

Buy

3

Hold

1

Sell

0

Strong Sell

0

12-Month Price Target

$15.00Low

$0.71Current

$15.00Avg Target上涨空间 2000.25%

$15.00High

合计: 4 · 买入占比: 75.0%

根据过去 3 个月内 4 位华尔街分析师，ENLV 共识评级为 Buy，12 个月平均目标价 $15.00 （较现价 $0.71 上涨空间 2000.25%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Enlivex Therapeutics Ltd.

$0.71+0.59%$17.4M #2

CollPlant Biotechnologies Ltd.

$0.37-0.27%$4.5M #3

Cadrenal Therapeutics, Inc. Common Stock

$4.21-5.18%$12.1M #4

CytoMed Therapeutics Limited

$1.15-10.85%$13.6M #5

Lisata Therapeutics, Inc.

$3.48+3.88%$31.7M #6

$2.22-13.62%$4.9M

股票表现

1D+0.59%

1W-13.95%

1M-7.25%

3M-37.35%

YTD+1.56%

1Y-24.02%

5Y-92.22%

关于 Enlivex Therapeutics Ltd.

CEOOren Hershkovitz

IPO DateJul 31, 2014

Employees71

CountryIL

Websiteenlivex.com

Enlivex Therapeutics Ltd. established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is curre…

Biotechnology HealthcareNASDAQIL

关于股票概览与关键数据

Enlivex Therapeutics Ltd.（ENLV）是 Biotechnology 行业的 Healthcare 类公司，于 Jul 31, 2014 在 NASDAQ 上市。截至最近交易日，ENLV 股价为 $0.71，市值约为 $17.4M。过去12个月累计回报 -24.02%，年初至今回报 +1.56%。

根据 4 位华尔街分析师，Enlivex Therapeutics Ltd. 股票共识评级为Buy，12个月平均目标价为 $15.00。2025 财年 Enlivex Therapeutics Ltd. 营收 —，净利润 $1.2B。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Enlivex Therapeutics Ltd.（ENLV）股价为 $0.71，在 NASDAQ 上市，52周区间为 $0.66 – $2.10。

ENLV 最新股价ENLV quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议